Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial

2014 ◽  
Vol 50 (18) ◽  
pp. 3098-3106 ◽  
Author(s):  
Michel Ducreux ◽  
Laetitia Dahan ◽  
Denis Smith ◽  
Dermot O’Toole ◽  
Céline Lepère ◽  
...  
Keyword(s):  
Phase Ii ◽  
Randomised Trial ◽  
Endocrine Tumours ◽  
Pancreatic Endocrine Tumours ◽  
Well Differentiated

18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours

2011 ◽  
Vol 32 (2) ◽  
pp. 91-97 ◽  
Author(s):  
Francesco Giammarile ◽  
Claire Billotey ◽  
Catherine Lombard-Bohas ◽  
Didier Le Bars ◽  
Claire Bournaud ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Endocrine Tumours ◽  
Positron Emission ◽  
Pancreatic Endocrine Tumours ◽  
18F Fdg ◽  
Well Differentiated

scholarly journals A Phase II Trial of Bevacizumab with Capecitabine in Progressive, Metastatic Well-Differentiated Digestive Endocrine Tumors (Better Study)

2012 ◽  
Vol 23 ◽  
pp. ix378
Author(s):  
T.A. Walter ◽  
E. Baudin ◽  
J.E. Kurtz ◽  
P. Ruszniewski ◽  
L. Bengrine-Lefevre ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Endocrine Tumors ◽  
Well Differentiated

scholarly journals Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumours

2002 ◽  
pp. 567-572 ◽  
Author(s):  
KY Lam ◽  
PS Leung
Keyword(s):  
Renin Angiotensin System ◽  
Receptor Protein ◽  
Pancreatic Ducts ◽  
Human Pancreas ◽  
Rt Pcr ◽  
Angiotensin System ◽  
Endocrine Tumours ◽  
Renin Angiotensin ◽  
Objective Evidence ◽  
Pancreatic Endocrine Tumours

OBJECTIVE: Evidence exists for the presence of a renin-angiotensin system (RAS) in the pancreas. The aims of this study were to prove the presence of an intrinsic RAS in the human pancreas and to analyse the role of such an RAS in pancreatic endocrine tumours (PETs). METHODS: Gene expression of key RAS components (angiotensinogen and angiotensin II receptors, namely AT1 and AT2) was investigated in human pancreas and in PETs by semi-quantitative RT-PCR and immunohistochemistry. RESULTS: Expression of mRNAs of RAS components was found in human pancreas and in PETs. Data from semi-quantitative RT-PCR analysis demonstrated an increase in the mRNA expression of angiotensinogen and AT2 receptor in PETs when compared with that in normal pancreas. By immunohistochemistry, angiotensinogen protein was predominantly localized in the pancreatic islets while AT1 receptor protein was in the pancreatic ducts. CONCLUSIONS: The data support the notion of the existence of an intrinsic RAS in the human pancreas. It also indicates, for the first time, that such a local pancreatic RAS is subject to regulation by PETs and its significant change may have pathophysiological relevance in patients with PETs.

The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours

Pancreatology ◽  
2013 ◽  
Vol 13 (3) ◽  
pp. S81-S82
Author(s):  
Claudio Ricci ◽  
Giovanni Taffurelli ◽  
Marielda D’Ambra ◽  
Salvatore Buscemi ◽  
Francesco Monari ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Ratio ◽  
Curative Surgery ◽  
Endocrine Tumours ◽  
Node Ratio ◽  
Pancreatic Endocrine Tumours

scholarly journals Etiology, Assessment and Management of WDHA (Watery Diarrhea, Hypokalemia, and Achlorhydria) and VIPoma

2021 ◽  
pp. 69-75
Author(s):  
Mohammed Salah Hussein ◽  
RIdha A. Bdulmohsen Al Shaqaqiq ◽  
Khaled Mubarak Aldhuaina ◽  
Azhar Abdullah Al-qattan ◽  
Salwah Mohammed Qaysi ◽  
...  
Keyword(s):  
Islet Cell ◽  
Watery Diarrhoea ◽  
Watery Diarrhea ◽  
Acid Base ◽  
Pancreatic Islet Cell ◽  
Endocrine Tumours ◽  
Pancreatic Endocrine Tumours ◽  
Prevalent Symptom ◽  
Wdha Syndrome

The syndrome of watery diarrhoea, hypokalemia, and achlorhydria (WDHA syndrome) is an uncommon disorder marked by severe, watery diarrhoea caused by non–beta pancreatic islet cell oversecretion of vasoactive intestinal peptide (VIP). The onset of the disease is gradual, and diagnosis is often months or years later. Long-term dehydration, electrolyte and acid-base abnormalities, and chronic renal failure are all linked to morbidity. Pancreatic endocrine tumours are extremely rare, with less than 10 incidences per million people. VIPomas are uncommon tumours that affect between 0.05 and 2.0 percent of people. The most prevalent symptom is diarrhoea, which affects at least 89 percent of patients. VIPoma is treated with a combination of medicine and surgery The goal of first medical treatment is to reduce symptoms and restore fluids and electrolytes as quickly as possible

Sign in / Sign up

Export Citation Format

Share Document